Selectively binds inner-mitochondrial cardiolipin, stabilizes electron transport chain super-complexes, reduces ROS, restores ATP production.
Reference facts
- Also known as
- Elamipretide, Bendavia, MTP-131
- Category
- Mitochondrial & Cellular Longevity
- Mechanism of action
- Selectively binds inner-mitochondrial cardiolipin, stabilizes electron transport chain super-complexes, reduces ROS, restores ATP production.
- Targets
- Cardiolipin (inner mitochondrial membrane)
- Indications under research or approved
- Primary mitochondrial myopathy, Barth syndrome, Heart failure (clinical trials)
- Regulatory status (reference entry)
- Investigational (FDA CRL 2020 for PMM; ongoing reformulation)
- Half-life
- ~3 hours (subcutaneous)
- Sequence notes
- Tetrapeptide D-Arg-2',6'-dimethyltyrosine-Lys-Phe-NH2. The non-natural Dmt residue and D-Arg confer cardiolipin selectivity.
- Molecular weight (Da)
- 640
- Originator / sponsor
- Stealth BioTherapeutics
- First reported
- 2004
- Origin
- Designed by Hazel Szeto at Cornell as part of the SS (Szeto-Schiller) peptide series.
Primary References
Explore research articles about SS-31
This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.